Key result
The HeartMate III LVAD demonstrated no mechanical failures, low hemolysis, and low thrombogenicity during six in vivo bovine studies lasting 27 to 59 days.
The HeartMate III LVAD demonstrated favorable hemodynamic performance, mechanical reliability, and hemocompatibility in preclinical in vitro and bovine models.
Answers are grounded in this paper and cite their sources.
Supports progression to human trials of HeartMate III LVAD; leaves open long-term safety and efficacy in patients.
A long-term, compact left ventricular assist device (LVAD), the HeartMate III, has been designed and fabricated, featuring a centrifugal pump with a magnetically levitated rotor. The pump has been optimized by in vitro testing to achieve a design point of 7 L/min against 135 mm Hg at high hydrodynamic efficiency (30%) and to be capable of up to 10 L/min under such a load. Furthermore, the pump has demonstrated no mechanical failures, low hemolysis (4-10 mg/dl plasma free Hb), and low thrombogenicity during six (40, 27, 59, 42, 27, and 49-day) in vivo bovine studies.
No takes yet. Share an insight, caveat, or question.
Bourque et al. (2001) studied this question. HeartMate III LVAD was evaluated on Mechanical failures, hemolysis, and thrombogenicity. The HeartMate III LVAD demonstrated no mechanical failures, low hemolysis, and low thrombogenicity during six in vivo bovine studies lasting 27 to 59 days.
Synapse has enriched 10 related papers. Consider them for comparative context: